27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ImmunoGen (NASDAQ:IMGN) focuses on antibody-drug conjugates for the treatment of cancer and the company said Thursday it will prioritize continued development of “Mivetuximab Soravtansine” targeting solid tumors
Mirvetuximab Soravtansine is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer.
ImmunoGen shares traded lwoer by 1.5% to $1.90 at time of publication.
Related Links:
Acer Therapeutics Shares Plunge On FDA Complete Response Letter
Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!